BioSpace News Archive

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.

Viracta Therapeutics, Inc. (Nasdaq: VIRX), today announced that the European Commission has granted an orphan drug designation (ODD) to nanatinostat and valganciclovir (Nana-val), the company’s all-oral combination product candidate, for the treatment of peripheral T-cell lymphoma (PTCL).

Neurelis, Inc., announced the recent online publication of a novel data analysis, evaluating the time interval between seizure clusters, or SEIzure interVAL (SEIVAL) in Epilepsia that indicates a significant increase in time between seizure clusters treated with VALTOCO® (diazepam nasal spray) CIV.

Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the “Company” or “Inspira Technologies”), a groundbreaking respiratory support technology company, announces the completion of an animal study that was conducted at Lahav C.R.O (contract research organization) by leading intensive care unit, or ICU, and respiratory specialists, who are members of Inspira’s Scientific Advisory Board.

BCV announces a major step in the development and evaluation of steerable mechatronic guidewires for stroke treatment – the GECKO System.

AceLink Therapeutics, Inc. (AceLink), an innovative biopharmaceutical company developing transformative therapies for genetic diseases, today announced it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for AL01211 as a treatment for Fabry disease.

The platelet concentration systems market is expected to gain promising growth across the assessment period of 2020-2030.

AMC Research is initiating a clinical trial for a promising new investigational treatment for Alzheimer’s disease (AD) in Matthews, N.C.

Miach Orthopaedics, Inc., a company transforming the treatment of anterior cruciate ligament tears from reconstruction to restoration with the Bridge-Enhanced ACL Restoration Implant, announced healthcare industry veteran Patrick McBrayer has been appointed president and chief executive officer.

Rite Aid Corporation will release financial results for its Fiscal 2023 Second Quarter, which ended Aug. 27, 2022, on Thursday, Sept. 29.